Let-7, an established tumor suppressor microRNA, plays a key role in lung tissue repair and the development of scarring, a ...

If your journey with pulmonary fibrosis were a movie, what best describes the genre? Horror? Comedy? Drama? Reality? Wait, how about a Hallmark movie? When I was diagnosed with idiopathic pulmonary ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

Columnist Sam Kirton pays tribute to his friend and IPF mentor, Pieter van den Assum, who passed away on May 17.

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is ...

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — ...

A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in ...

A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF). Treatment boosted the ...

The abnormal accumulation of immune plasma cells in the lungs — and their subsequent generation of damaging antibodies — may be a key driver of idiopathic pulmonary fibrosis (IPF), according to new ...

Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness — may be a new way to slow the progression of idiopathic pulmonary fibrosis ...

Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and then transplanted back into their lungs to treat idiopathic pulmonary fibrosis (IPF), ...